Lessons learned from a clinical trial

被引：9

作者：

Armstrong, PW

Newby, LK

Granger, CB

Lee, KL

Simes, RJ

Van de Werf, F

White, HD

Califf, RM

机构：

[1] Univ Alberta, Dept Med, Edmonton, AB T6G 2H7, Canada

[2] Duke Clin Res Inst, Durham, NC USA

[3] Natl Hlth & Med Res Council, Sydney, NSW, Australia

[4] Univ Hosp Gasthuisberg, Gasthuisberg, Belgium

[5] Auckland City Hosp, Auckland, New Zealand

来源：

CIRCULATION | 2004年 / 110卷 / 23期

关键词：

trials; clinical; multicenter studies; biomedical research; ethics; research;

D O I：

10.1161/01.CIR.0000148680.83392.50

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：3610 / 3614

页数：5

共 28 条

[11] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].

Gent, M ;

Beaumont, D ;

Blanchard, J ;

Bousser, MG ;

Coffman, J ;

Easton, JD ;

Hampton, JR ;

Harker, LA ;

Janzon, L ;

Kusmierek, JJE ;

Panak, E ;

Roberts, RS ;

Shannon, JS ;

Sicurella, J ;

Tognoni, G ;

Topol, EJ ;

Verstraete, M ;

Warlow, C .

LANCET, 1996, 348 (9038) :1329-1339

[12] GUIDELINES ON AUTHORSHIP OF MEDICAL PAPERS [J].

HUTH, EJ .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (02) :269-274

[13] Oral glycoprotein IIb/IIIa antagonists: New insights from the SYMPHONY trial [J].

McGuire, DK ;

Newby, LK .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2000, 10 (02) :111-119

[14] The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials [J].

Moher, D ;

Schulz, KF ;

Altman, D .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (15) :1987-1991

[15] Monitoring and ensuring safety during clinical research [J].

Morse, MA ;

Califf, RM ;

Sugarman, J .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (09) :1201-1205

[16]

Newby K, 2001, CIRCULATION, V103, P1727

[17] Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary syndromes (SYMPHONY) trial [J].

Newby, LK .

AMERICAN HEART JOURNAL, 1999, 138 (02) :210-218

[18] The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events [J].

Newby, LK ;

Califf, RM ;

White, HD ;

Harrington, RA ;

Van de Werf, F ;

Granger, CB ;

Simes, RJ ;

Hasselblad, V ;

Armstrong, PW .

AMERICAN JOURNAL OF MEDICINE, 2002, 112 (08) :647-658

[19] Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. [J].

O'Neill, WW ;

Serruys, P ;

Knudtson, M ;

van Es, GA ;

Timmis, GC ;

van der Zwaan, C ;

Kleiman, J ;

Gong, JJ ;

Roecker, EB ;

Dreiling, R ;

Alexander, J ;

Anders, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) :1316-1324

[20] Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors [J].

Peter, K ;

Schwarz, M ;

Ylänne, J ;

Kohler, B ;

Moser, M ;

Nordt, T ;

Salbach, P ;

Kübler, W ;

Bode, C .

BLOOD, 1998, 92 (09) :3240-3249

← 1 2 3 →